Riskpilot← Back to searchSign inGet full accessSCREENCANCER AS
ASActiveOrg 994878271Vingvegen 2, 4050 SolaDiagnostic imaging services and medical laboratory activities · NACE 8691Est. 20094 employeeswww.screencancer.com
Revenue 2024
NOK 6,4M
+10% vs 2023
EBITDA margin
-23.9%
-16% vs 2023
Equity ratio
40.8%
Financial strength
Net profit 2024
NOK -1,8M
+15% vs 2023
| Revenue | NOK 6,4M | +10% |
| EBITDA | NOK -1,5M | -16% |
| Net profit | NOK -1,8M | +15% |
| Total assets | NOK 20,5M | +120% |
| Equity | NOK 8,4M | +361% |
| Employees | 4 | — |
Legal name
SCREENCANCER AS
Org number
994878271
Legal form
Aksjeselskap
NACE code
8691 · Diagnostic imaging services and medical laboratory activities
Founded
10. desember 2009
Share capital
NOK 833 598
Employees
4 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Screening og diagnostikk av kreft og annen virksomhet som har naturlig tilknytning til dette, herunder å delta i andre selskaper med lignende virksomhet.
Address
Vingvegen 2, 4050 Sola
Website
www.screencancer.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 230 | 4 005 | 5 298 | 5 847 | 6 420 |
| Staff expenses | −2 817 | −2 678 | −3 264 | −3 473 | −3 730 |
| EBITDA | −2 540 | −2 645 | −1 622 | −1 323 | −1 536 |
| Depreciation & amort. | −60 | −33 | −28 | −14 | −35 |
| EBIT | −2 599 | −2 678 | −1 650 | −1 337 | −1 571 |
| Net financials | −410 | −361 | −238 | −811 | −252 |
| Profit before tax | −3 009 | −3 039 | −1 888 | −2 148 | −1 823 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −3 009 | −3 039 | −1 888 | −2 148 | −1 823 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 7 844 | 9 095 | 10 187 | 9 311 | 20 501 |
| Equity | 758 | 719 | −1 057 | −3 205 | 8 373 |
| Long-term debt | 4 790 | 6 718 | 9 578 | 10 070 | 7 944 |
| Short-term debt | 2 296 | 1 657 | 1 667 | 2 446 | 4 183 |
| Total debt | 7 086 | 8 375 | 11 245 | 12 516 | 12 128 |
EBITDA margin
-23.9%
This company
15.8%
Market median
-251% vs market
20202024
Equity ratio
40.8%
This company
38.2%
Market median
+7% vs market
20202024
Return on equity
-21.8%
This company
18.4%
Market median
-218% vs market
20202024
Net profit margin
-28.4%
This company
8.1%
Market median
-451% vs market
20202024
Asset turnover
0.31×
This company
1.12×
Market median
-72% vs market
20202024
Debt / equity
1.45×
This company
0.62×
Market median
-134% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MV Chief Executive Officer | Chief Executive Officer | 2010 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2020 | |
| Board of Directors | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Deepx Diagnostics Inc. | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SCREENCANCER AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mette Valeur | Chief Executive Officer | 0 companies |
| Hans Johan Hekland | Chairman | 0 companies |
| Christian Horn | Board of Directors | 0 companies |